IMDX Oncocyte Corp Insider Trading

Major 10% shareholder BROADWOOD PARTNERS buys 570,184 shares ($2.0M) at $3.56 avg across 6 transactions

BROADWOOD PARTNERS, L.P., a 10% owner, executed 6 separate purchases totaling 570,184 shares for $2,032,251.44 between April 16–27, 2026, at a blended average price of $3.56. The current price of $3.84 is 54.7% below the 52-week high of $8.48, and the stock is down 44.3% over the past 90 days, though up 7.9% over the past 30 days. The company is unprofitable (full-year net income was negative $10,854,000.00 with latest-quarter revenue of $260,000.00) but showed annual revenue growth of +115.6%. Broadwood's cross-ticker track record shows a 0.00% win rate at the 90-day mark with average returns of -14.9%, and its prior 5 trades at IMDX remain outcome-unmeasurable. The scale of this capital commitment—$2.0M added to an already substantial 12.68M-share position—alongside accumulation across depressed price levels and a period of recent gains (30-day +7.9%) follows multiple purchases by the same filer within days, warranting close monitoring of whether this reflects changed conviction about company fundamentals or portfolio allocation.

Broadwood Partners (10% owner) purchased 182,861 shares across 3 dates for $652,875.63; stock now -53.0% from 52-week high

Broadwood Partners executed 3 separate purchases totaling 182,861 shares between April 16–20, 2026 at a blended average price of $3.57, adding 1.5% to its existing 11.93M share position. The timing is concerning: the stock is currently trading at $3.99, down 53.0% from its 52-week high of $8.48 and down 6.3% over the past 30 days. Across the insider's cross-ticker track record, prior buys show an average 90-day return of -18.2% with a 0.00% win rate, and at IMDX specifically, the two prior buys in February 2026 posted 30-day returns of -15.0% and -34.0%. The company itself faces fundamental headwinds: while annual revenue grew 115.6%, the most recent quarter generated only $260,000 in revenue against a $-10.9M net loss, and the company was unprofitable over its most recent full fiscal year. The purchase does not reverse the negative momentum or address the underlying profitability challenges.

IMDX: Broadwood Partners acquires 521,739 shares for $2,999,999.25; stock down 34.2% from 52-week high despite 25.2% revenue growth.

Broadwood Partners, a 10% owner, purchased 521,739 shares at $5.75 on 2026-02-10 for $2,999,999.25, expanding holdings to 11,931,839 shares (+4.6% increase). The acquisition occurs against a backdrop of significant recent price weakness: the stock is -34.2% from its 52-week high of $8.48 and has declined -22.8% over the past 30 days. Simultaneously, the company reported 25.2% annual revenue growth, yet remains unprofitable with a net loss of $10,854,000.00 in its most recent full fiscal year and minimal quarterly revenue of $260,000.00. The cross-ticker track record shows this insider's prior 20 open-market buys yielded an average 90-day return of +10.4% with a 100.00% win rate, though zero measurable same-ticker outcomes exist. The open-market purchase at a price 3.0% above the current market price of $5.58 occurs during a steep drawdown, creating a key interpretive tension: whether the large position increase reflects conviction in the underlying business fundamentals or is simply a function of the insider's portfolio allocation discipline at price levels significantly above recent market levels.

10% owner Patrick W. Smith buys 1,077,600 OCX shares at $2.05; holdings rise to 3.26M (+49.4%); 4 prior buys in 9 days.

Patrick W. Smith, a 10% owner of Oncocyte Corp, purchased 1,077,600 shares at $2.05 on 2025-02-07, increasing his holdings by 49.4% to 3,258,485 shares. This transaction is part of an intense buying cluster: Smith has executed 5 separate purchases in the past 14 days, alongside 2 other insiders also acquiring shares in the same window, signaling coordinated accumulation at the company. The stock currently trades at $2.37, down 29.5% from its 52-week high of $3.36 but up 7.2% over the past 30 days. Smith's cross-ticker track record shows his 8 prior open-market buys yielded an average 30-day return of -4.7%, whereas his 12 prior sells averaged a +5.6% 30-day return—a pattern suggesting he has been more effective at exiting positions than entering them. Fundamentally, Oncocyte is unprofitable (latest quarter net income: $-13,493,000.00) with minimal revenue ($115,000.00 in the most recent quarter), though the company achieved 56.9% annual revenue growth. The cluster activity and substantial position increase warrant monitoring of whether this aggressive accumulation reflects informed conviction or broader market pressure on a pre-revenue-stage oncology company.

CFO James Andrea S. bought 97,561 shares of OCX at $2.05 (+181.8% to holdings); stock at $2.37, down 29.5% from 52-week high.

CFO James Andrea S. purchased 97,561 shares at $2.05 on 2025-02-07, increasing his holdings from 53,670 to 151,231 shares. The transaction occurred while the stock trades at $2.37, approximately 29.5% below its 52-week high of $3.36, following a 90-day decline of 19.4%. His prior trade at OCX on 2024-10-02 resulted in a 90-day loss of 19.9%, and his cross-ticker track record shows a 0.00% win rate at the 90-day mark across 2 prior buys. The company reported revenue of $115,000.00 in its latest quarter with net losses of $13.5M and was unprofitable over its most recent full fiscal year, despite annual revenue growth of 56.9%. A cluster pattern shows 2 other insiders also bought within the past 14 days, suggesting broader executive interest at current valuations.

10% owner BROADWOOD PARTNERS bought 5,165,695 shares for $10,589,674.75 at $2.05; holdings surge 82.7%

BROADWOOD PARTNERS, L.P. executed 4 separate purchases totaling 5,165,695 shares (5.17M shares) for $10,589,674.75 ($10.6M) at $2.05 per share on 2025-02-06, increasing its holdings from 6,244,405 shares to 11,410,100 shares (+82.7%). The transaction occurs as the stock trades at $2.07, down 38.4% from its 52-week high of $3.36 and down 31.0% over the past 90 days. At the same-ticker level, BROADWOOD's prior 4 buys at OCX show mixed timing outcomes: 2 of 4 achieved positive 90-day returns, suggesting moderate historical accuracy at this specific security. The company's fundamentals show negative profitability ($-13.5M net income in the most recent full fiscal year) and minimal quarterly revenue ($115.0K), though annual growth reached 56.9%, which may indicate early-stage development. A cluster pattern is present, with 2 other insiders also buying within the past 14 days, suggesting coordinated interest at current price levels among multiple stakeholders.

10% owner Smith purchases 915 shares in 2 transactions at blended avg $2.01 amid stock decline

Patrick W. Smith, a 10% owner of Oncocyte Corp, made 2 separate purchases totaling 915 shares for $1,839.40 at a blended average price of $2.01 on 2025-01-31 and 2025-02-04. The current price of $2.13 is -36.6% from the 52-week high and down -10.1% over the past 30 days. This purchase occurred during a period of negative stock momentum, though the transaction amounts remain modest relative to Smith's 1,795,071-share post-transaction holdings. Smith's cross-ticker track record shows 6 prior open-market buys with an average 30-day return of -4.7%, and his 5 prior trades at OCX remain unmeasurable for outcome assessment. The company is unprofitable with a $-13.5M net loss in the latest quarter, though it reported +56.9% annual revenue growth.

PATRICK W SMITH (10% owner) buys 4,198 shares at $2.01 in 2 transactions; stock down -13.0% in 30 days, -31.0% in 90 days.

PATRICK W SMITH, a 10% shareholder of Oncocyte Corp, made 2 separate purchases totaling 4,198 shares for $8,437.98 at an average price of $2.01 on January 29–30, 2025, increasing his holdings from 1,789,958 to 1,794,156 shares. The timing of these purchases is notable: the stock has declined -13.0% over the prior 30 days and -31.0% over the prior 90 days from current levels, trading 38.4% below its 52-week high of $3.36. Oncocyte is severely unprofitable (net income of $-13.5M in the latest fiscal year) with minimal revenue ($115.0K last quarter), though annual growth was strong at +56.9%. Across all tickers, SMITH's prior 5 open-market buys returned an average of -4.7% within 30 days; his prior 4 purchases at OCX specifically remain unmeasurable in outcome.

10% owner Patrick W. Smith bought 16,055 shares in 3 transactions at $2.08–$2.15 (avg $2.12), raising stake to 1.79M shares (+0.9%)

Patrick W. Smith, a 10% stakeholder at Oncocyte Corp, made 3 separate purchases totaling 16,055 shares for $34,114.42 between January 13 and 14, 2025, at a blended average price of $2.12. The stock currently trades at $2.20, reflecting a -36.2% decline from its 52-week high of $3.45. Smith's cross-ticker track record shows 1 prior buy and 19 prior sells with a 0.00% 90-day well-timed rate on those sells, indicating his prior sales have not preceded stock declines—his selling history has not been predictive. At Oncocyte specifically, he has only one prior transaction (a buy on December 26, 2024) with outcome timing not yet measurable. The company posted quarterly revenue of $115,000.00 and a net loss of $-13,493,000.00, with annual revenue growth of +56.9% but persistent unprofitability, creating a contrast between growth and financial performance that warrants attention to how the insider's accumulation aligns with company trajectory.

10% Owner SMITH PATRICK W bought 90,219 shares of OCX at $2.13 on 2024-12-26; stock now at $2.11, -41.4% from 52-week high.

Smith, a 10% owner, purchased 90,219 shares at $2.13, increasing his holdings from 1,683,684 to 1,773,903 shares. The transaction occurred while Oncocyte's stock has declined 41.4% from its 52-week high and lost 26.7% over the past 90 days, though Smith's purchase price of $2.13 is only marginally above the current $2.11. The company's fundamentals remain challenged: revenue of $115,000 in the latest quarter with a net loss of $13.5M and an annual market cap of just $35.5M, despite 56.9% annual revenue growth. Smith's cross-ticker track record shows 20 prior open-market sells with a 0.00% well-timed rate (none followed by stock declines), suggesting his historical sell decisions have not aligned with subsequent downward price movement. The significance of this purchase lies in insider demand during a prolonged decline, but the lack of historical predictive value in Smith's cross-ticker sell timing and the company's unprofitable state warrant cautious interpretation.